AURA vs NVS

Novartis AG (NVS) offers the better valuation at 21.

3x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Aura Biosciences, Inc. (AURA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +94.

0%, compared to -56. 7% for Aura Biosciences, Inc. (AURA). Over 10 years, the gap is even starker: NVS returned +187. 2% versus AURA's -56. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.

45β versus Aura Biosciences, Inc. 's 1. 68β — meaning AURA is approximately 271% more volatile than NVS relative to the S&P 500. On balance sheet safety, Aura Biosciences, Inc. (AURA) carries a lower debt/equity ratio of 13% versus 80% for Novartis AG — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Novartis AG grew EPS 22.

5% year-over-year, compared to -0. 6% for Aura Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novartis AG (NVS) is the more profitable company, earning 25.

6% net margin versus 0. 0% for Aura Biosciences, Inc. — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus 0. 0% for AURA. At the gross margin level — before operating expenses — NVS leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AURA: 165.

2% to $17. 00.

In this comparison, NVS (2.

6% yield) pays a dividend. AURA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

45), 2. 6% yield, +187. 2% 10Y return). Aura Biosciences, Inc. (AURA) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVS: +187. 2%, AURA: -56. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

NVS pays a dividend while AURA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.